FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:231-238 January 25, 1996 Number 4 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Overexpression of the gene for the multidrug-resistance–associated protein (MRP) has been linked with resistance to chemotherapeutic agents (multidrug resistance) in vitro. The expression of MRP by neuroblastoma cells correlates with N-myc oncogene amplification, a well-established prognostic indicator in patients with neuroblastoma.

Methods To relate MRP gene expression to established prognostic markers and the clinical outcome of neuroblastoma, we analyzed MRP expression in specimens of primary tumors from 60 patients with neuroblastoma.

Results Levels of MRP gene expression were significantly higher in tumors with N-myc amplification than in tumors without such amplification (P<0.001). High levels of MRP expression were strongly associated with reductions in both survival and event-free survival (P<0.001) in the overall study population and in subgroups of patients without N-myc amplification and patients with localized disease. For the overall study population, the five-year cumulative survival rates in the groups with high and low levels of MRP expression were 57 percent (95 percent confidence interval, 37 to 78 percent) and 94 percent (95 percent confidence interval, 86 to 100 percent), respectively. In contrast, expression of the MDR1 multidrug-resistance gene was not predictive of survival or event-free survival. After adjustment by multivariate analysis for the effects of N-myc amplification and other prognostic indicators, high levels of MRP expression retained significant prognostic value for poor survival (relative hazard, 14.9; P = 0.01) and poor event-free survival (relative hazard, 9.7; P = 0.004), whereas N-myc amplification had no prognostic value.

Conclusions High levels of MRP gene expression in patients with neuroblastoma correlate strongly with poor outcome. The findings suggest that expression of this multidrug-resistance gene accounts for the association between N-myc amplification and reduced survival.

Source Information

From the Children's Leukaemia and Cancer Research Centre, University of New South Wales and Prince of Wales Children's Hospital, Sydney, Australia (M.D.N., S.B.B., G.M.M., M.H.); the Department of Gastroenterology, Prince of Wales Hospital, Sydney, Australia (P.S.H.); and the Department of Pediatrics, Northwestern University Medical School and Children's Memorial Hospital, Chicago (S.L.C.).

Address reprint requests to Dr. Michelle Haber at the Children's Leukaemia and Cancer Research Centre, Prince of Wales Children's Hospital, High St., Randwick, NSW 2031, Australia.

Full Text of this Article

This article has been cited by other articles:

• Van Maerken, T., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J. Jr, Cuvelier, C. A., Marine, J.-C., De Paepe, A., Bracke, M., Speleman, F., Vandesompele, J. (2009). Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53. JNCI J Natl Cancer Inst 101: 1562-1574 [Abstract] [Full Text]  
• Burkhart, C. A., Watt, F., Murray, J., Pajic, M., Prokvolit, A., Xue, C., Flemming, C., Smith, J., Purmal, A., Isachenko, N., Komarov, P. G., Gurova, K. V., Sartorelli, A. C., Marshall, G. M., Norris, M. D., Gudkov, A. V., Haber, M. (2009). Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma. Cancer Res. 69: 6573-6580 [Abstract] [Full Text]  
• YOSHIDA, T., MIYOSHI, T., SEIKE, J.-I., YAMAI, H., TAKECHI, H., YUASA, Y., TANGOKU, A. (2009). Gene Expression Changes in a Chemoresistant Model with Human Esophageal Cancer Xenografts Using cDNA Microarray. Anticancer Res 29: 1163-1168 [Abstract] [Full Text]  
• Xue, C., Haber, M., Flemming, C., Marshall, G. M., Lock, R. B., MacKenzie, K. L., Gurova, K. V., Norris, M. D., Gudkov, A. V. (2007). p53 Determines Multidrug Sensitivity of Childhood Neuroblastoma. Cancer Res. 67: 10351-10360 [Abstract] [Full Text]  
• Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., Seeger, R. C. (2006). Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification.. JNCI J Natl Cancer Inst 98: 1193-1203 [Abstract] [Full Text]  
• Chesler, L., Schlieve, C., Goldenberg, D. D., Kenney, A., Kim, G., McMillan, A., Matthay, K. K., Rowitch, D., Weiss, W. A. (2006). Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. Cancer Res. 66: 8139-8146 [Abstract] [Full Text]  
• Deeley, R. G., Westlake, C., Cole, S. P. C. (2006). Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins.. Physiol. Rev. 86: 849-899 [Abstract] [Full Text]  
• Dallas, S., Miller, D. S., Bendayan, R. (2006). Multidrug resistance-associated proteins: expression and function in the central nervous system.. Pharmacol. Rev. 58: 140-161 [Abstract] [Full Text]  
• Haber, M., Smith, J., Bordow, S. B., Flemming, C., Cohn, S. L., London, W. B., Marshall, G. M., Norris, M. D. (2006). Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma. JCO 24: 1546-1553 [Abstract] [Full Text]  
• Tang, X. X., Zhao, H., Kung, B., Kim, D. Y., Hicks, S. L., Cohn, S. L., Cheung, N.-K., Seeger, R. C., Evans, A. E., Ikegaki, N. (2006). The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma.. Cancer Res. 66: 2826-2833 [Abstract] [Full Text]  
• Carr, J., Bell, E., Pearson, A. D.J., Kees, U. R., Beris, H., Lunec, J., Tweddle, D. A. (2006). Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse. Cancer Res. 66: 2138-2145 [Abstract] [Full Text]  
• Lindenmaier, H., Becker, M., Haefeli, W. E., Weiss, J. (2005). INTERACTION OF PROGESTINS WITH THE HUMAN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2). Drug Metab. Dispos. 33: 1576-1579 [Abstract] [Full Text]  
• Santana, V. M., Furman, W. L., Billups, C. A., Hoffer, F., Davidoff, A. M., Houghton, P. J., Stewart, C. F. (2005). Improved Response in High-Risk Neuroblastoma With Protracted Topotecan Administration Using a Pharmacokinetically Guided Dosing Approach. JCO 23: 4039-4047 [Abstract] [Full Text]  
• Norris, M. D., Smith, J., Tanabe, K., Tobin, P., Flemming, C., Scheffer, G. L., Wielinga, P., Cohn, S. L., London, W. B., Marshall, G. M., Allen, J. D., Haber, M. (2005). Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Molecular Cancer Therapeutics 4: 547-553 [Abstract] [Full Text]  
• Tian, X., Zamek-Gliszczynski, M. J., Zhang, P., Brouwer, K. L. R. (2004). Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes. Mol. Pharmacol. 66: 1004-1010 [Abstract] [Full Text]  
• Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A., Brenner, M. K. (2004). A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 101: 14228-14233 [Abstract] [Full Text]  
• Don, S., Verrills, N. M., Liaw, T. Y.E., Liu, M. L.M., Norris, M. D., Haber, M., Kavallaris, M. (2004). Neuronal-associated microtubule proteins class III {beta}-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs. Molecular Cancer Therapeutics 3: 1137-1146 [Abstract] [Full Text]  
• Hansford, L. M., Thomas, W. D., Keating, J. M., Burkhart, C. A., Peaston, A. E., Norris, M. D., Haber, M., Armati, P. J., Weiss, W. A., Marshall, G. M. (2004). Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification. Proc. Natl. Acad. Sci. USA 101: 12664-12669 [Abstract] [Full Text]  
• He, X., Ee, P. L. R., Coon, J. S., Beck, W. T. (2004). Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20. Clin. Cancer Res. 10: 4652-4660 [Abstract] [Full Text]  
• Burkhart, C. A., Cheng, A. J., Madafiglio, J., Kavallaris, M., Mili, M., Marshall, G. M., Weiss, W. A., Khachigian, L. M., Norris, M. D., Haber, M. (2003). Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma. JNCI J Natl Cancer Inst 95: 1394-1403 [Abstract] [Full Text]  
• Lockhart, A. C., Tirona, R. G., Kim, R. B. (2003). Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy. Molecular Cancer Therapeutics 2: 685-698 [Abstract] [Full Text]  
• Blanc, E., Goldschneider, D., Ferrandis, E., Barrois, M., Le Roux, G., Leonce, S., Douc-Rasy, S., Benard, J., Raguenez, G. (2003). MYCN Enhances P-gp/MDR1 Gene Expression in the Human Metastatic Neuroblastoma IGR-N-91 Model. Am. J. Pathol. 163: 321-331 [Abstract] [Full Text]  
• Weinstein, J. L., Katzenstein, H. M., Cohn, S. L. (2003). Advances in the Diagnosis and Treatment of Neuroblastoma. The Oncologist 8: 278-292 [Abstract] [Full Text]  
• Ohishi, Y., Oda, Y., Uchiumi, T., Kobayashi, H., Hirakawa, T., Miyamoto, S., Kinukawa, N., Nakano, H., Kuwano, M., Tsuneyoshi, M. (2002). ATP-binding Cassette Superfamily Transporter Gene Expression in Human Primary Ovarian Carcinoma. Clin. Cancer Res. 8: 3767-3775 [Abstract] [Full Text]  
• Bown, N (2001). Neuroblastoma tumour genetics: clinical and biological aspects. J. Clin. Pathol. 54: 897-910 [Abstract] [Full Text]  
• DeCory, H. H., Piech-Dumas, K. M., Sheu, S.-S., Federoff, H. J., Anders, M. W. (2001). Efflux of Glutathione Conjugate of Monochlorobimane from Striatal and Cortical Neurons. Drug Metab. Dispos. 29: 1256-1262 [Abstract] [Full Text]  
• Peck, R. A., Hewett, J., Harding, M. W., Wang, Y.-M., Chaturvedi, P. R., Bhatnagar, A., Ziessman, H., Atkins, F., Hawkins, M. J. (2001). Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin. JCO 19: 3130-3141 [Abstract] [Full Text]  
• Young, L. C., Campling, B. G., Cole, S. P. C., Deeley, R. G., Gerlach, J. H. (2001). Multidrug Resistance Proteins MRP3, MRP1, and MRP2 in Lung Cancer: Correlation of Protein Levels with Drug Response and Messenger RNA Levels. Clin. Cancer Res. 7: 1798-1804 [Abstract] [Full Text]  
• Johnson, D. R., Finch, R. A., Lin, Z. P., Zeiss, C. J., Sartorelli, A. C. (2001). The Pharmacological Phenotype of Combined Multidrug-Resistance mdr1a/1b- and mrp1-deficient Mice. Cancer Res. 61: 1469-1476 [Abstract] [Full Text]  
• Cohn, S. L., London, W. B., Huang, D., Katzenstein, H. M., Salwen, H. R., Reinhart, T., Madafiglio, J., Marshall, G. M., Norris, M. D., Haber, M. (2000). MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN. JCO 18: 3604-3613 [Abstract] [Full Text]  
• Raggi, C. C., Maggi, M., Renzi, D., Calabrò, A., Bagnoni, M. L., Scaruffi, P., Tonini, G. P., Pazzagli, M., De Bernardi, B., Bernini, G., Serio, M., Orlando, C. (2000). Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome. J. Clin. Endocrinol. Metab. 85: 3866-3873 [Abstract] [Full Text]  
• Hinoshita, E., Uchiumi, T., Taguchi, K.-i., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., Sugimachi, K., Kuwano, M. (2000). Increased Expression of an ATP-binding Cassette Superfamily Transporter, Multidrug Resistance Protein 2, in Human Colorectal Carcinomas. Clin. Cancer Res. 6: 2401-2407 [Abstract] [Full Text]  
• Sietsma, H., Veldman, R. J., Kolk, D. v. d., Ausema, B., Nijhof, W., Kamps, W., Vellenga, E., Kok, J. W. (2000). 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol Chemosensitizes Neuroblastoma Cells for Taxol and Vincristine. Clin. Cancer Res. 6: 942-948 [Abstract] [Full Text]  
• Misawa, A., Hosoi, H., Arimoto, A., Shikata, T., Akioka, S., Matsumura, T., Houghton, P. J., Sawada, T. (2000). N-Myc Induction Stimulated by Insulin-like Growth Factor I through Mitogen-activated Protein Kinase Signaling Pathway in Human Neuroblastoma Cells. Cancer Res. 60: 64-69 [Abstract] [Full Text]  
• van den Elsen, J. M. H., Kuntz, D. A., Hoedemaeker, F. J., Rose, D. R. (1999). Antibody C219 recognizes an alpha -helical epitope on P-glycoprotein. Proc. Natl. Acad. Sci. USA 96: 13679-13684 [Abstract] [Full Text]  
• Raggi, C. C., Bagnoni, M. L., Tonini, G. P., Maggi, M., Vona, G., Pinzani, P., Mazzocco, K., De Bernardi, B., Pazzagli, M., Orlando, C. (1999). Real-Time Quantitative PCR for the Measurement of MYCN Amplification in Human Neuroblastoma with the TaqMan Detection System. Clin. Chem. 45: 1918-1924 [Abstract] [Full Text]  
• Glick, R. D., Swendeman, S. L., Coffey, D. C., Rifkind, R. A., Marks, P. A., Richon, V. M., La Quaglia, M. P. (1999). Hybrid Polar Histone Deacetylase Inhibitor Induces Apoptosis and CD95/CD95 Ligand Expression in Human Neuroblastoma. Cancer Res. 59: 4392-4399 [Abstract] [Full Text]  
• Maris, J. M., Matthay, K. K. (1999). Molecular Biology of Neuroblastoma. JCO 17: 2264-2264 [Abstract] [Full Text]  
• Gilbert, J., Haber, M., Bordow, S. B., Marshall, G. M., Norris, M. D. (1999). Use of Tumor-Specific Gene Expression for the Differential Diagnosis of Neuroblastoma from Other Pediatric Small Round-Cell Malignancies. Am. J. Pathol. 155: 17-21 [Abstract] [Full Text]  
• Huhn, S. L., Mohapatra, G., Bollen, A., Lamborn, K., Prados, M. D., Feuerstein, B. G. (1999). Chromosomal Abnormalities in Glioblastoma Multiforme by Comparative Genomic Hybridization: Correlation with Radiation Treatment Outcome. Clin. Cancer Res. 5: 1435-1443 [Abstract] [Full Text]  
• Dwivedi, R. S., Wang, L.-J., Mirkin, B. L. (1999). S-Adenosylmethionine Synthetase Is Overexpressed in Murine Neuroblastoma Cells Resistant to Nucleoside Analogue Inhibitors of S-Adenosylhomocysteine Hydrolase: A Novel Mechanism of Drug Resistance. Cancer Res. 59: 1852-1856 [Abstract] [Full Text]  
• Young, L. C., Campling, B. G., Voskoglou-Nomikos, T., Cole, S. P. C., Deeley, R. G., Gerlach, J. H. (1999). Expression of Multidrug Resistance Protein-related Genes in Lung Cancer: Correlation with Drug Response. Clin. Cancer Res. 5: 673-680 [Abstract] [Full Text]  
• Roelofsen, H, Hooiveld, G., Koning, H, Havinga, R, Jansen, P., Muller, M (1999). Glutathione S-conjugate transport in hepatocytes entering the cell cycle is preserved by a switch in expression from the apical MRP2 to the basolateral MRP1 transporting protein. J. Cell Sci. 112: 1395-1404 [Abstract]  
• Toth, K., Vaughan, M. M., Schwartz, G., Winston, J. S., Skenderis, B. S. II, Slocum, H. K., Rustum, Y. M. (1998). Expression of the MRP and MDRI Multidrug Resistance Gene Products in 160 Untreated Human Carcinomas Studied by Immunohistochemical Methods in Formalin-Paraffin Sections. INT J SURG PATHOL 6: 145-154 [Abstract]  
• den Boer, M.L., Pieters, R., Kazemier, K.M., Rottier, M.M.A., Zwaan, C.M., Kaspers, G.J.L., Janka-Schaub, G., Henze, G., Creutzig, U., Scheper, R.J., Veerman, A.J.P. (1998). Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia. Blood 91: 2092-2098 [Abstract] [Full Text]  
• Zhan, Z., Sandor, V. A., Gamelin, E., Regis, J., Dickstein, B., Wilson, W., Fojo, A. T., Bates, S. E. (1997). Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay. Blood 89: 3795-3800 [Abstract] [Full Text]  
• Duhem, C., Ries, F., Dicato, M. (1996). What does Multidrug Resistance (MDR) Expression Mean in the Clinic?. The Oncologist 1: 151-158 [Abstract] [Full Text]  
• Rosenberg, M. F., Mao, Q., Holzenburg, A., Ford, R. C., Deeley, R. G., Cole, S. P. C. (2001). The Structure of the Multidrug Resistance Protein 1 (MRP1/ABCC1). CRYSTALLIZATION AND SINGLE-PARTICLE ANALYSIS. J. Biol. Chem. 276: 16076-16082 [Abstract] [Full Text]